JDP2 and ovarian carcinoma: As shown in Fig. 7c–f and Supplementary Tables 2–3, statistical analysis revealed that JDP2 levels were significantly correlated with CDDP resistance (P < 0.001; r = 0.37), relapse (P = 0.002; r = 0.25), FIGO stage (P = 0.009; r = 0.21), SLC7A11 expression (P = 0.008; r = 0.22) and GSH level (P = 0.007; r = 0.482), but was associated with shorter overall/relapse-free survival in patients with ovarian cancer treated with platinum-based therapy (both P < 0.05).